PEARLITOL® mannitol - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Continuous commitment to Mannitol development to Support the growth of the Pharmaceutical Market Segments

Mannitol has a share of the most desirable qualities that formulators seek in mineral, sugar or even polymeric excipients: notably a characteristic low chemical reactivity, an extraordinarily low level of hygroscopicity making it one of the "driest" products for moisture sensitive formulation, coupled with a pleasant taste and mouthfeel.

Since the 1970’s, Roquette has been continuously working on improving the remarkable intrinsic properties by providing mannitol with DC properties, self disintegration, low endotoxin level, leading to the creation of the largest mannitol range for the pharmaceutical industry: PEARLITOL® C, SD, DC, FLASH and PF.

Company name:          ROQUETTE

Website:                      www.roquettepharma.com

E-mail:                         pharma.business.unit@roquette.com

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
FindPharma Custom Search

Click here